ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
Biomarkers for the development of new medications for cocaine dependence.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Examining cocaine use reductions and long-term outcomes in two clinical trials of continuing care for cocaine dependence.Journal of substance use and addiction treatment · 2024Trial
- D2 autoreceptors gate vulnerability to cocaine use disorder.bioRxiv : the preprint server for biology · 2026Article
- Prelimbic cortex and nucleus accumbens core resting state signaling dynamics as a biomarker for cocaine seeking behaviors.Addiction neuroscience · 2023Article
- Biomarkers of Relapse in Cocaine Use Disorder: A Narrative Review.Brain sciences · 2022Review
- A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.Translational psychiatry · 2022Article
- A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus.Nature protocols · 2022Article
- Neuroimaging Biomarkers in Schizophrenia.The American journal of psychiatry · 2021Review
- Methylation Patterns of theFrontiers in psychiatry · 2020Article
- Central GLP-1 receptors: Novel molecular targets for cocaine use disorder.Physiology & behavior · 2019Review
- A Clinician's Perspective on Biomarkers.Focus (American Psychiatric Publishing) · 2018Review
- Pathways to precision medicine in smoking cessation treatments.Neuroscience letters · 2018Review
- Central and Peripheral Biomarkers of Stress Response for Addiction Risk and Relapse Vulnerability.Trends in molecular medicine · 2018Review
- Biosignature Discovery for Substance Use Disorders Using Statistical Learning.Trends in molecular medicine · 2018Review
- Extracellular dopamine, acetylcholine, and activation of dopamine D1 and D2 receptors after selective breeding for cocaine self-administration in rats.Psychopharmacology · 2017Article
- Social threat exposure in juvenile mice promotes cocaine-seeking by altering blood clotting and brain vasculature.Addiction biology · 2017Article
- Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.Scientific reports · 2017Article
- Glutamate and Brain Glutaminases in Drug Addiction.Neurochemical research · 2017Review
- [18F]-Fluorodeoxyglucose-Positron Emission Tomography in Rats with Prolonged Cocaine Self-Administration Suggests Potential Brain Biomarkers for Addictive Behavior.Frontiers in psychiatry · 2017Article
- Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes.Brain imaging and behavior · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
Abstract
There has been significant progress in personalized drug development. In large part, this has taken place in the oncology field and been due to the ability of researchers/clinicians to discover and develop novel drug development tools (DDTs), such as biomarkers. In cancer treatment research, biomarkers have permitted a more accurate pathophysiological characterization of an individual patient, and have enabled practitioners to target mechanistically the right drug, to the right patient, at the right time. Similar to cancer, patients with substance use disorders (SUDs) present clinically with heterogeneous symptomatology and respond variably to therapeutic interventions. If comparable biomarkers could be identified and developed for SUDs, significant diagnostic and therapeutic advances could be made. In this review, we highlight current opportunities and difficulties pertaining to the identification and development of biomarkers for SUDs. We focus on cocaine dependence as an example. Putative diagnostic, pharmacodynamic (PD), and predictive biomarkers for cocaine dependence are discussed across a range of methodological approaches. A possible cocaine-dependent clinical outcome assessment (COA)--another type of defined DDT--is also discussed. At present, biomarkers for cocaine dependence are in their infancy. Much additional research will be needed to identify, validate, and qualify these putative tools prior to their potential use for medications development and/or application to clinical practice. However, with a large unmet medical need and an estimated market size of several hundred million dollars per year, if developed, biomarkers for cocaine dependence will hold tremendous value to both industry and public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.